6 days ago
Guardant Health (GH) Receives a Buy from Craig-Hallum
Craig-Hallum analyst William Bonello maintained a Buy rating on Guardant Health (GH – Research Report) today. The company's shares opened today at $38.45.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bonello is a 4-star analyst with an average return of 8.3% and a 47.27% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Guardant Health, Veracyte, and GeneDx Holdings.
Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $60.00, representing a 56.05% upside. In a report released on May 16, Bank of America Securities also maintained a Buy rating on the stock with a $60.00 price target.
GH market cap is currently $4.73B and has a P/E ratio of -11.41.
Based on the recent corporate insider activity of 149 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year. Earlier this month, Tariq Musa, a Director at GH sold 116.00 shares for a total of $4,644.64.
